



## Clinical trial results:

### A 16-Week, Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily PF-06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2019-000218-12 |
| Trial protocol           | SK HU PL BG    |
| Global end of trial date | 07 July 2021   |

#### Results information

|                                |              |
|--------------------------------|--------------|
| Result version number          | v1 (current) |
| This version publication date  | 18 June 2022 |
| First version publication date | 18 June 2022 |

#### Trial information

##### Trial identification

|                       |          |
|-----------------------|----------|
| Sponsor protocol code | C3421005 |
|-----------------------|----------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT03985293 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Pfizer Inc.  |
| Sponsor organisation address | 235 E 42nd Street, New York, United States, NY 10017   |
| Public contact               | Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com |
| Scientific contact           | Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |              |
|--|--------------|
| Analysis stage                                       | Final        |
| Date of interim/final analysis                       | 07 July 2021 |
| Is this the analysis of the primary completion data? | No           |
| Global end of trial reached?                         | Yes          |
| Global end of trial date                             | 07 July 2021 |
| Was the trial ended prematurely?                     | No           |

Notes:

## General information about the trial

Main objective of the trial:

To compare the effect of multiple dose levels of danuglipron (PF-06882961) versus placebo on glycated hemoglobin (HbA1c) in subjects with type 2 diabetes mellitus (T2DM) on stable doses of metformin and/or diet and exercise.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed.

Background therapy: -

Evidence for comparator: -

|   |              |
|---|--------------|
| Actual start date of recruitment                          | 07 July 2020 |
| Long term follow-up planned                               | No           |
| Independent data monitoring committee (IDMC) involvement? | No           |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |  |
|--------------------------------------|--|
| Country: Number of subjects enrolled | Bulgaria: 6                                |
| Country: Number of subjects enrolled | Canada: 29                                 |
| Country: Number of subjects enrolled | Hungary: 72                                |
| Country: Number of subjects enrolled | Korea, Democratic People's Republic of: 10 |
| Country: Number of subjects enrolled | Poland: 36                                 |
| Country: Number of subjects enrolled | Slovakia: 36                               |
| Country: Number of subjects enrolled | Taiwan: 14                                 |
| Country: Number of subjects enrolled | United States: 208                         |
| Worldwide total number of subjects   | 411  |
| EEA total number of subjects         | 150  |

Notes:

### Subjects enrolled per age group

|   |   |
|---|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23          | 0 |

|                           |     |
|---------------------------|-----|
| months)                   |     |
| Children (2-11 years)     | 0   |
| Adolescents (12-17 years) | 0   |
| Adults (18-64 years)      | 291 |
| From 65 to 84 years       | 120 |
| 85 years and over         | 0   |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 859 subjects were screened in the study, of which, 412 subjects were randomized, and 411 subjects were treated with PF-06882961 (Danuglipron)/placebo; 1 subject randomized to the PF-06882961 120 mg BID group was not treated.

### Period 1

|                              |                         |
|------------------------------|-------------------------|
| Period 1 title               | DOUBLE-BLIND TREATMENT  |
| Is this the baseline period? | Yes                     |
| Allocation method            | Randomised - controlled |
| Blinding used                | Double blind            |
| Roles blinded                | Subject, Investigator   |

### Arms

|                              |         |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes     |
| <b>Arm title</b>             | Placebo |

Arm description:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.

|  |          |
|--|----------|
| Arm type                               | Placebo  |
| Investigational medicinal product name | Placebo  |
| Investigational medicinal product code |          |
| Other name                             |          |
| Pharmaceutical forms                   | Tablet   |
| Routes of administration               | Oral use |

Dosage and administration details:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.

|                  |                       |
|------------------|-----------------------|
| <b>Arm title</b> | PF-06882961 2.5mg BID |
|------------------|-----------------------|

Arm description:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | danuglipron  |
| Investigational medicinal product code | PF-06882961  |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

|                  |                      |
|------------------|----------------------|
| <b>Arm title</b> | PF-06882961 10mg BID |
|------------------|----------------------|

Arm description:

PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|  |                      |
|--|----------------------|
| Investigational medicinal product name   | danuglipron          |
| Investigational medicinal product code   | PF-06882961          |
| Other name   |                      |
| Pharmaceutical forms   | Tablet               |
| Routes of administration   | Oral use             |
| Dosage and administration details:   |                      |
| PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks. |                      |
| <b>Arm title</b>   | PF-06882961 40mg BID |

Arm description:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | danuglipron  |
| Investigational medicinal product code | PF-06882961  |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

|                  |                      |
|------------------|----------------------|
| <b>Arm title</b> | PF-06882961 80mg BID |
|------------------|----------------------|

Arm description:

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | danuglipron  |
| Investigational medicinal product code | PF-06882961  |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

|                  |                       |
|------------------|-----------------------|
| <b>Arm title</b> | PF-06882961 120mg BID |
|------------------|-----------------------|

Arm description:

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | danuglipron  |
| Investigational medicinal product code | PF-06882961  |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

| Number of subjects in period 1       | Placebo | PF-06882961 2.5mg<br>BID | PF-06882961 10mg<br>BID |
|--------------------------------------|---------|--------------------------|-------------------------|
| Started                              | 66      | 68                       | 68                      |
| Completed                            | 57      | 54                       | 63                      |
| Not completed                        | 9       | 14                       | 5                       |
| Consent withdrawn by subject         | -       | 4                        | 2                       |
| Adverse event, non-fatal             | 5       | 2                        | 3                       |
| Unspecified                          | 1       | 2                        | -                       |
| Lost to follow-up                    | 1       | 3                        | -                       |
| No Longer Meets Eligibility Criteria | 1       | 1                        | -                       |
| Protocol deviation                   | 1       | 2                        | -                       |

| Number of subjects in period 1       | PF-06882961 40mg<br>BID | PF-06882961 80mg<br>BID | PF-06882961<br>120mg BID |
|--------------------------------------|-------------------------|-------------------------|--------------------------|
| Started                              | 71                      | 67                      | 71                       |
| Completed                            | 57                      | 47                      | 38                       |
| Not completed                        | 14                      | 20                      | 33                       |
| Consent withdrawn by subject         | -                       | 1                       | 7                        |
| Adverse event, non-fatal             | 8                       | 15                      | 24                       |
| Unspecified                          | 2                       | 1                       | -                        |
| Lost to follow-up                    | 3                       | 3                       | 1                        |
| No Longer Meets Eligibility Criteria | 1                       | -                       | -                        |
| Protocol deviation                   | -                       | -                       | 1                        |

## Period 2

|                              |                         |
|------------------------------|-------------------------|
| Period 2 title               | FOLLOW-UP               |
| Is this the baseline period? | No                      |
| Allocation method            | Randomised - controlled |
| Blinding used                | Double blind            |
| Roles blinded                | Subject, Investigator   |

## Arms

|                              |         |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes     |
| Arm title                    | Placebo |

Arm description:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.

|  |          |
|--|----------|
| Arm type                               | Placebo  |
| Investigational medicinal product name | Placebo  |
| Investigational medicinal product code |          |
| Other name                             |          |
| Pharmaceutical forms                   | Tablet   |
| Routes of administration               | Oral use |

Dosage and administration details:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.

|                  |                       |
|------------------|-----------------------|
| <b>Arm title</b> | PF-06882961 2.5mg BID |
|------------------|-----------------------|

Arm description:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | danuglipron  |
| Investigational medicinal product code | PF-06882961  |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

|                  |                      |
|------------------|----------------------|
| <b>Arm title</b> | PF-06882961 10mg BID |
|------------------|----------------------|

Arm description:

PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | danuglipron  |
| Investigational medicinal product code | PF-06882961  |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

|                  |                      |
|------------------|----------------------|
| <b>Arm title</b> | PF-06882961 40mg BID |
|------------------|----------------------|

Arm description:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks.  
Titration was implemented.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | danuglipron  |
| Investigational medicinal product code | PF-06882961  |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks.  
Titration was implemented.

|                  |                      |
|------------------|----------------------|
| <b>Arm title</b> | PF-06882961 80mg BID |
|------------------|----------------------|

Arm description:

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks.  
Titration was implemented.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | danuglipron  |
| Investigational medicinal product code | PF-06882961  |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

---

**Dosage and administration details:**

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

|                  |                       |
|------------------|-----------------------|
| <b>Arm title</b> | PF-06882961 120mg BID |
|------------------|-----------------------|

**Arm description:**

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | danuglipron  |
| Investigational medicinal product code | PF-06882961  |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

**Dosage and administration details:**

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

| <b>Number of subjects in period 2</b> | Placebo | PF-06882961 2.5mg<br>BID | PF-06882961 10mg<br>BID |
|---------------------------------------|---------|--------------------------|-------------------------|
| Started                               | 57      | 54                       | 63                      |
| Completed                             | 57      | 54                       | 62                      |
| Not completed                         | 0       | 0                        | 1                       |
| Lost to follow-up                     | -       | -                        | 1                       |

| <b>Number of subjects in period 2</b> | PF-06882961 40mg<br>BID | PF-06882961 80mg<br>BID | PF-06882961 120mg<br>BID |
|---------------------------------------|-------------------------|-------------------------|--------------------------|
| Started                               | 57                      | 47                      | 38                       |
| Completed                             | 57                      | 47                      | 38                       |
| Not completed                         | 0                       | 0                       | 0                        |
| Lost to follow-up                     | -                       | -                       | -                        |



## Baseline characteristics

### Reporting groups

|   |                       |
|---|-----------------------|
| Reporting group title   | Placebo               |
| Reporting group description:<br>Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.                |                       |
| Reporting group title   | PF-06882961 2.5mg BID |
| Reporting group description:<br>PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.                            |                       |
| Reporting group title   | PF-06882961 10mg BID  |
| Reporting group description:<br>PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.                             |                       |
| Reporting group title   | PF-06882961 40mg BID  |
| Reporting group description:<br>PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.  |                       |
| Reporting group title   | PF-06882961 80mg BID  |
| Reporting group description:<br>PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.  |                       |
| Reporting group title   | PF-06882961 120mg BID |
| Reporting group description:<br>PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented. |                       |

| Reporting group values                        | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID |
|---|---------|-----------------------|----------------------|
| Number of subjects                            | 66      | 68                    | 68                   |
| Age Categorical<br>Units: Subjects            |         |                       |                      |
| Adults (18-64 years)                          | 50      | 47                    | 48                   |
| Adults (65-84 years)                          | 16      | 21                    | 20                   |
| Age Continuous<br>Units: Years                |         |                       |                      |
| arithmetic mean                               | 57.9    | 58.9                  | 58.1                 |
| standard deviation                            | ± 10.27 | ± 9.30                | ± 9.43               |
| Sex: Female, Male<br>Units: Subjects          |         |                       |                      |
| Male  | 33      | 38                    | 35                   |
| Female  | 33      | 30                    | 33                   |
| Race/Ethnicity, Customized<br>Units: Subjects |         |                       |                      |
| White   | 57      | 57                    | 53                   |
| Black or African American                     | 2       | 4                     | 10                   |
| Asian   | 5       | 7                     | 4                    |
| Native Hawaiian or Other Pacific Islander     | 1       | 0                     | 0                    |
| Not reported                                  | 1       | 0                     | 1                    |
| Ethnicity (NIH/OMB)                           |         |                       |                      |

|                         |    |    |    |
|-------------------------|----|----|----|
| Units: Subjects         |    |    |    |
| Hispanic or Latino      | 24 | 22 | 17 |
| Not Hispanic or Latino  | 42 | 46 | 50 |
| Unknown or Not Reported | 0  | 0  | 1  |

| Reporting group values                        | PF-06882961 40mg<br>BID | PF-06882961 80mg<br>BID | PF-06882961<br>120mg BID |
|---|-------------------------|-------------------------|--------------------------|
| Number of subjects                            | 71                      | 67                      | 71                       |
| Age Categorical<br>Units: Subjects            |                         |                         |                          |
| Adults (18-64 years)                          | 47                      | 47                      | 52                       |
| Adults (65-84 years)                          | 24                      | 20                      | 19                       |
| Age Continuous<br>Units: Years                |                         |                         |                          |
| arithmetic mean                               | 59.6                    | 58.4                    | 58.8                     |
| standard deviation                            | ± 8.58                  | ± 9.18                  | ± 9.43                   |
| Sex: Female, Male<br>Units: Subjects          |                         |                         |                          |
| Male  | 34                      | 35                      | 34                       |
| Female  | 37                      | 32                      | 37                       |
| Race/Ethnicity, Customized<br>Units: Subjects |                         |                         |                          |
| White   | 58                      | 59                      | 59                       |
| Black or African American                     | 6                       | 1                       | 4                        |
| Asian   | 6                       | 6                       | 7                        |
| Native Hawaiian or Other Pacific<br>Islander  | 0                       | 0                       | 1                        |
| Not reported                                  | 1                       | 1                       | 0                        |
| Ethnicity (NIH/OMB)<br>Units: Subjects        |                         |                         |                          |
| Hispanic or Latino                            | 24                      | 23                      | 18                       |
| Not Hispanic or Latino                        | 47                      | 44                      | 52                       |
| Unknown or Not Reported                       | 0                       | 0                       | 1                        |

| Reporting group values                        | Total |  |  |
|---|-------|--|--|
| Number of subjects                            | 411   |  |  |
| Age Categorical<br>Units: Subjects            |       |  |  |
| Adults (18-64 years)                          | 291   |  |  |
| Adults (65-84 years)                          | 120   |  |  |
| Age Continuous<br>Units: Years                |       |  |  |
| arithmetic mean                               | -     |  |  |
| standard deviation                            | -     |  |  |
| Sex: Female, Male<br>Units: Subjects          |       |  |  |
| Male  | 209   |  |  |
| Female  | 202   |  |  |
| Race/Ethnicity, Customized<br>Units: Subjects |       |  |  |
| White   | 343   |  |  |
| Black or African American                     | 27    |  |  |

|   |     |  |  |
|---|-----|--|--|
| Asian                                     | 35  |  |  |
| Native Hawaiian or Other Pacific Islander | 2   |  |  |
| Not reported                              | 4   |  |  |
| Ethnicity (NIH/OMB)                       |     |  |  |
| Units: Subjects                           |     |  |  |
| Hispanic or Latino                        | 128 |  |  |
| Not Hispanic or Latino                    | 281 |  |  |
| Unknown or Not Reported                   | 2   |  |  |

## End points

### End points reporting groups

|   |                       |
|---|-----------------------|
| Reporting group title   | Placebo               |
| Reporting group description:<br>Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.                |                       |
| Reporting group title   | PF-06882961 2.5mg BID |
| Reporting group description:<br>PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.                            |                       |
| Reporting group title   | PF-06882961 10mg BID  |
| Reporting group description:<br>PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.                             |                       |
| Reporting group title   | PF-06882961 40mg BID  |
| Reporting group description:<br>PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.  |                       |
| Reporting group title   | PF-06882961 80mg BID  |
| Reporting group description:<br>PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.  |                       |
| Reporting group title   | PF-06882961 120mg BID |
| Reporting group description:<br>PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented. |                       |
| Reporting group title   | Placebo               |
| Reporting group description:<br>Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.   |                       |
| Reporting group title   | PF-06882961 2.5mg BID |
| Reporting group description:<br>PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.   |                       |
| Reporting group title   | PF-06882961 10mg BID  |
| Reporting group description:<br>PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks.  |                       |
| Reporting group title   | PF-06882961 40mg BID  |
| Reporting group description:<br>PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.   |                       |
| Reporting group title   | PF-06882961 80mg BID  |
| Reporting group description:<br>PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.   |                       |
| Reporting group title   | PF-06882961 120mg BID |
| Reporting group description:<br>PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.  |                       |

**Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16**

|                 |  |
|-----------------|--|
| End point title | Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16 |
|-----------------|--|

End point description:

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline, Week 16

| End point values                             | Placebo               | PF-06882961 2.5mg BID  | PF-06882961 10mg BID   | PF-06882961 40mg BID   |
|--|-----------------------|------------------------|------------------------|------------------------|
| Subject group type                           | Reporting group       | Reporting group        | Reporting group        | Reporting group        |
| Number of subjects analysed                  | 52                    | 52                     | 61                     | 55                     |
| Units: Percent                               |                       |                        |                        |                        |
| least squares mean (confidence interval 90%) | -0.02 (-0.22 to 0.19) | -0.49 (-0.70 to -0.28) | -0.91 (-1.11 to -0.72) | -1.03 (-1.23 to -0.83) |

| End point values                             | PF-06882961 80mg BID   | PF-06882961 120mg BID  |  |  |
|--|------------------------|------------------------|--|--|
| Subject group type                           | Reporting group        | Reporting group        |  |  |
| Number of subjects analysed                  | 46                     | 38                     |  |  |
| Units: Percent                               |                        |                        |  |  |
| least squares mean (confidence interval 90%) | -0.96 (-1.18 to -0.74) | -1.18 (-1.41 to -0.95) |  |  |

**Statistical analyses**

|   |                                      |
|---|--------------------------------------|
| Statistical analysis title              | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 104                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.0071                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.47                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.76                                |
| upper limit                             | -0.18                                |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 113                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.9                                |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.18                               |
| upper limit                             | -0.62                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 107                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -1.01                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.3                                |
| upper limit                             | -0.73                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 98                                  |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.94                               |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -1.24   |
| upper limit         | -0.65   |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 90                                   |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | < 0.0001                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -1.16                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -1.47                                |
| upper limit                             | -0.86                                |

### Secondary: Percentage of Subjects Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels

|   |  |
|---|--|
| End point title   | Percentage of Subjects Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels |
| End point description:  |  |
| HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Baseline, Week 16   |  |

| End point values              | Placebo         | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID |
|-------------------------------|-----------------|-----------------------|----------------------|----------------------|
| Subject group type            | Reporting group | Reporting group       | Reporting group      | Reporting group      |
| Number of subjects analysed   | 52              | 52                    | 61                   | 55                   |
| Units: Percentage of Subjects |                 |                       |                      |                      |
| number (not applicable)       | 7.7             | 30.8                  | 54.1                 | 58.2                 |

|                  |                      |                       |  |  |
|------------------|----------------------|-----------------------|--|--|
| End point values | PF-06882961 80mg BID | PF-06882961 120mg BID |  |  |
|------------------|----------------------|-----------------------|--|--|

|                               |                 |                 |  |  |
|-------------------------------|-----------------|-----------------|--|--|
| Subject group type            | Reporting group | Reporting group |  |  |
| Number of subjects analysed   | 46              | 38              |  |  |
| Units: Percentage of Subjects |                 |                 |  |  |
| number (not applicable)       | 65.2            | 60.5            |  |  |

## Statistical analyses

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 104                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| Method                                  | Regression, Logistic                 |
| Parameter estimate                      | Odds ratio (OR)                      |
| Point estimate                          | 5.11                                 |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | 1.84                                 |
| upper limit                             | 14.18                                |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 113                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| Method                                  | Regression, Logistic                |
| Parameter estimate                      | Odds ratio (OR)                     |
| Point estimate                          | 16.85                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | 6.18                                |
| upper limit                             | 45.93                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 107                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| Method                                  | Regression, Logistic                |
| Parameter estimate                      | Odds ratio (OR)                     |
| Point estimate                          | 18.79                               |



|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | 7.03    |
| upper limit         | 50.21   |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 98                                  |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| Method                                  | Regression, Logistic                |
| Parameter estimate                      | Odds ratio (OR)                     |
| Point estimate                          | 23.97                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | 8.66                                |
| upper limit                             | 66.39                               |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 90                                   |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| Method                                  | Regression, Logistic                 |
| Parameter estimate                      | Odds ratio (OR)                      |
| Point estimate                          | 24.46                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | 8.72                                 |
| upper limit                             | 68.57                                |

## Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2

|                 |   |
|-----------------|---|
| End point title | Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2 |
|-----------------|---|

End point description:

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 2

| <b>End point values</b>                      | Placebo                | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|------------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group        | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 65                     | 64                       | 67                      | 67                      |
| Units: Percent                               |                        |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.09 (-0.17 to -0.01) | -0.18 (-0.26 to -0.09)   | -0.31 (-0.39 to -0.23)  | -0.29 (-0.37 to -0.21)  |

| <b>End point values</b>                      | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 63                      | 69                       |  |  |
| Units: Percent                               |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -0.33 (-0.41 to -0.24)  | -0.35 (-0.43 to -0.28)   |  |  |

### Statistical analyses

| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
|---|--------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 129                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.1578                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.09                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.19                                |
| upper limit                             | 0.01                                 |

| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 132                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0003                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.22                               |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -0.32   |
| upper limit         | -0.12   |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 132                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0013                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.2                                |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.3                                |
| upper limit                             | -0.1                                |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 128                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.24                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.34                               |
| upper limit                             | -0.14                               |

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 120mg BID versus Placebo |
| Comparison groups                 | Placebo v PF-06882961 120mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 134                   |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | < 0.0001              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -0.26                 |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -0.36                 |
| upper limit                             | -0.16                 |

## Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4

|   |   |
|---|---|
| End point title   | Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4 |
| End point description:  |   |
| HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |   |
| End point type  | Secondary   |
| End point timeframe:  |   |
| Baseline, Week 4  |   |

| End point values                             | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 60                    | 58                       | 68                      | 63                      |
| Units: Percent                               |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.08 (-0.19 to 0.04) | -0.38 (-0.50 to -0.26)   | -0.51 (-0.62 to -0.39)  | -0.63 (-0.74 to -0.52)  |

| End point values                             | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 54                      | 60                       |  |  |
| Units: Percent                               |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -0.58 (-0.70 to -0.46)  | -0.64 (-0.75 to -0.53)   |  |  |

## Statistical analyses

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 118                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.0013                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.3                                 |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.46                                |
| upper limit                             | -0.15                                |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 128                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.43                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.58                               |
| upper limit                             | -0.28                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 123                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.55                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.7                                |
| upper limit                             | -0.4                                |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 114                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.5                                |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.66                               |
| upper limit                             | -0.35                               |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 120                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | < 0.0001                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.56                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.71                                |
| upper limit                             | -0.41                                |

## Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6

|   |   |
|---|---|
| End point title   | Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6 |
| End point description:  |   |
| HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |   |
| End point type  | Secondary   |
| End point timeframe:  |   |
| Baseline, Week 6  |   |

| <b>End point values</b>                      | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 60                    | 55                       | 66                      | 59                      |
| Units: Percent                               |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.07 (-0.21 to 0.07) | -0.47 (-0.61 to -0.34)   | -0.71 (-0.84 to -0.57)  | -0.84 (-0.97 to -0.71)  |

| <b>End point values</b>                      | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 51                      | 52                       |  |  |
| Units: Percent                               |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -0.79 (-0.93 to -0.65)  | -0.84 (-0.98 to -0.71)   |  |  |

## Statistical analyses

| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
|---|--------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 115                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.0004                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.4                                 |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.59                                |
| upper limit                             | -0.22                                |

| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 126                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.64                               |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -0.81   |
| upper limit         | -0.46   |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 119                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.77                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.95                               |
| upper limit                             | -0.59                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 111                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.72                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.91                               |
| upper limit                             | -0.53                               |

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 120mg BID versus Placebo |
| Comparison groups                 | Placebo v PF-06882961 120mg BID      |



|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 112                   |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | < 0.0001              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -0.77                 |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -0.95                 |
| upper limit                             | -0.59                 |

## Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8

|                        |   |
|------------------------|---|
| End point title        | Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8   |
| End point description: | HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |
| End point type         | Secondary   |
| End point timeframe:   | Baseline, Week 8  |

| End point values                             | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 56                    | 51                       | 66                      | 58                      |
| Units: Percent                               |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.13 (-0.29 to 0.03) | -0.50 (-0.66 to -0.34)   | -0.78 (-0.93 to -0.62)  | -0.97 (-1.13 to -0.82)  |

| End point values                             | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 45                      | 42                       |  |  |
| Units: Percent                               |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -0.92 (-1.09 to -0.76)  | -1.02 (-1.18 to -0.86)   |  |  |

## Statistical analyses

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 107                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.0054                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.37                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.59                                |
| upper limit                             | -0.15                                |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 122                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.65                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.86                               |
| upper limit                             | -0.44                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 114                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.84                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.06                               |
| upper limit                             | -0.63                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 101                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.8                                |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.02                               |
| upper limit                             | -0.57                               |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 98                                   |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | < 0.0001                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.89                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -1.11                                |
| upper limit                             | -0.67                                |

## Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12

|   |  |
|---|--|
| End point title   | Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 |
| End point description:  |  |
| HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Baseline, Week 12   |  |

| <b>End point values</b>                      | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 55                    | 53                       | 63                      | 58                      |
| Units: Percent                               |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.09 (-0.28 to 0.10) | -0.53 (-0.72 to -0.34)   | -0.88 (-1.06 to -0.70)  | -1.06 (-1.25 to -0.88)  |

| <b>End point values</b>                      | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 46                      | 38                       |  |  |
| Units: Percent                               |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -0.91 (-1.12 to -0.71)  | -1.11 (-1.32 to -0.91)   |  |  |

### Statistical analyses

| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 118                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.79                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.05                               |
| upper limit                             | -0.54                               |

| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
|---|--------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 108                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.0061                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.44                                |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -0.71   |
| upper limit         | -0.18   |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 101                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.83                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.1                                |
| upper limit                             | -0.56                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 113                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.98                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.24                               |
| upper limit                             | -0.72                               |

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 120mg BID versus Placebo |
| Comparison groups                 | Placebo v PF-06882961 120mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 93                    |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | < 0.0001              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -1.03                 |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -1.3                  |
| upper limit                             | -0.75                 |

## Secondary: Change From Baseline in Fasting Plasma Glucose at Week 2

|   |  |
|---|--|
| End point title   | Change From Baseline in Fasting Plasma Glucose at Week 2 |
| End point description:  |  |
| The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 milligram per deciliter (mg/dL) to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Baseline, Week 2  |  |

| End point values                             | Placebo                | PF-06882961<br>2.5mg BID  | PF-06882961<br>10mg BID   | PF-06882961<br>40mg BID   |
|--|------------------------|---------------------------|---------------------------|---------------------------|
| Subject group type                           | Reporting group        | Reporting group           | Reporting group           | Reporting group           |
| Number of subjects analysed                  | 65                     | 64                        | 67                        | 68                        |
| Units: mg/dL                                 |                        |                           |                           |                           |
| least squares mean (confidence interval 90%) | -5.58 (-12.66 to 1.49) | -22.72 (-29.78 to -15.65) | -21.96 (-28.91 to -15.01) | -27.79 (-34.60 to -20.98) |

| End point values                             | PF-06882961<br>80mg BID   | PF-06882961<br>120mg BID  |  |  |
|--|---------------------------|---------------------------|--|--|
| Subject group type                           | Reporting group           | Reporting group           |  |  |
| Number of subjects analysed                  | 63                        | 68                        |  |  |
| Units: mg/dL                                 |                           |                           |  |  |
| least squares mean (confidence interval 90%) | -24.18 (-31.28 to -17.08) | -30.92 (-37.66 to -24.17) |  |  |

## Statistical analyses

|                            |                                      |
|----------------------------|--------------------------------------|
| Statistical analysis title | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups          | Placebo v PF-06882961 2.5mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 129                   |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | = 0.0014              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -17.13                |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -25.94                |
| upper limit                             | -8.33                 |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 132                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0021                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -16.38                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -25.08                              |
| upper limit                             | -7.67                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 133                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -22.2                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -30.88                              |
| upper limit                             | -13.53                              |

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 80mg BID versus Placebo |
|-----------------------------------|-------------------------------------|

|   |                                |
|---|--------------------------------|
| Comparison groups                       | Placebo v PF-06882961 80mg BID |
| Number of subjects included in analysis | 128                            |
| Analysis specification                  | Pre-specified                  |
| Analysis type                           | superiority                    |
| P-value                                 | = 0.0006                       |
| Method                                  | Mixed models analysis          |
| Parameter estimate                      | Difference in LS Mean          |
| Point estimate                          | -18.59                         |
| Confidence interval                     |                                |
| level                                   | 90 %                           |
| sides                                   | 2-sided                        |
| lower limit                             | -27.43                         |
| upper limit                             | -9.76                          |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 133                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | < 0.0001                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -25.33                               |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -34                                  |
| upper limit                             | -16.67                               |

#### **Secondary: Change From Baseline in Fasting Plasma Glucose at Week 4**

|                        |   |
|------------------------|---|
| End point title        | Change From Baseline in Fasting Plasma Glucose at Week 4  |
| End point description: | The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |
| End point type         | Secondary   |
| End point timeframe:   |   |
| Baseline, Week 4       |   |



| <b>End point values</b>                      | Placebo                | PF-06882961<br>2.5mg BID  | PF-06882961<br>10mg BID   | PF-06882961<br>40mg BID   |
|--|------------------------|---------------------------|---------------------------|---------------------------|
| Subject group type                           | Reporting group        | Reporting group           | Reporting group           | Reporting group           |
| Number of subjects analysed                  | 60                     | 58                        | 68                        | 62                        |
| Units: mg/dL                                 |                        |                           |                           |                           |
| least squares mean (confidence interval 90%) | -5.98 (-13.62 to 1.66) | -17.77 (-25.46 to -10.09) | -24.66 (-31.98 to -17.35) | -33.42 (-40.83 to -26.00) |

| <b>End point values</b>                      | PF-06882961<br>80mg BID   | PF-06882961<br>120mg BID  |  |  |
|--|---------------------------|---------------------------|--|--|
| Subject group type                           | Reporting group           | Reporting group           |  |  |
| Number of subjects analysed                  | 55                        | 60                        |  |  |
| Units: mg/dL                                 |                           |                           |  |  |
| least squares mean (confidence interval 90%) | -33.34 (-41.25 to -25.44) | -34.06 (-41.52 to -26.00) |  |  |

### Statistical analyses

| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID     |
| Number of subjects included in analysis | 118                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0468                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -11.79                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -21.55                              |
| upper limit                             | -2.04                               |

| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 128                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0012                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -18.68                              |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -28.12  |
| upper limit         | -9.25   |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 122                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -27.44                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -37.03                              |
| upper limit                             | -17.85                              |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 115                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -27.36                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -37.22                              |
| upper limit                             | -17.51                              |

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 120mg BID versus Placebo |
| Comparison groups                 | Placebo v PF-06882961 120mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 120                   |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | < 0.0001              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -28.09                |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -37.72                |
| upper limit                             | -18.45                |

## Secondary: Change From Baseline in Fasting Plasma Glucose at Week 6

|                        |   |
|------------------------|---|
| End point title        | Change From Baseline in Fasting Plasma Glucose at Week 6  |
| End point description: | The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |
| End point type         | Secondary   |
| End point timeframe:   | Baseline, Week 6  |

| End point values                             | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID   | PF-06882961<br>40mg BID   |
|--|-----------------------|--------------------------|---------------------------|---------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group           | Reporting group           |
| Number of subjects analysed                  | 60                    | 55                       | 66                        | 60                        |
| Units: mg/dL                                 |                       |                          |                           |                           |
| least squares mean (confidence interval 90%) | -0.88 (-8.62 to 6.86) | -16.78 (-24.67 to -8.89) | -26.41 (-33.88 to -18.94) | -30.89 (-38.47 to -23.30) |

| End point values                             | PF-06882961<br>80mg BID   | PF-06882961<br>120mg BID  |  |  |
|--|---------------------------|---------------------------|--|--|
| Subject group type                           | Reporting group           | Reporting group           |  |  |
| Number of subjects analysed                  | 51                        | 53                        |  |  |
| Units: mg/dL                                 |                           |                           |  |  |
| least squares mean (confidence interval 90%) | -28.36 (-36.51 to -20.21) | -32.65 (-40.44 to -24.87) |  |  |

## Statistical analyses

|                            |                                      |
|----------------------------|--------------------------------------|
| Statistical analysis title | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups          | Placebo v PF-06882961 2.5mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 115                   |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | = 0.0091              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -15.9                 |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -25.9                 |
| upper limit                             | -5.9                  |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 126                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -25.53                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -35.18                              |
| upper limit                             | -15.89                              |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 120                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -30.01                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -39.8                               |
| upper limit                             | -20.21                              |

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 80mg BID versus Placebo |
|-----------------------------------|-------------------------------------|

|   |                                |
|---|--------------------------------|
| Comparison groups                       | Placebo v PF-06882961 80mg BID |
| Number of subjects included in analysis | 111                            |
| Analysis specification                  | Pre-specified                  |
| Analysis type                           | superiority                    |
| P-value                                 | < 0.0001                       |
| Method                                  | Mixed models analysis          |
| Parameter estimate                      | Difference in LS Mean          |
| Point estimate                          | -27.48                         |
| Confidence interval                     |                                |
| level                                   | 90 %                           |
| sides                                   | 2-sided                        |
| lower limit                             | -37.63                         |
| upper limit                             | -17.33                         |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 113                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | < 0.0001                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -31.77                               |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -41.77                               |
| upper limit                             | -21.78                               |

## Secondary: Change From Baseline in Fasting Plasma Glucose at Week 8

|                        |   |
|------------------------|---|
| End point title        | Change From Baseline in Fasting Plasma Glucose at Week 8  |
| End point description: | The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |
| End point type         | Secondary   |
| End point timeframe:   |   |
| Baseline, Week 8       |   |

| <b>End point values</b>                         | Placebo                    | PF-06882961<br>2.5mg BID    | PF-06882961<br>10mg BID      | PF-06882961<br>40mg BID      |
|---|----------------------------|-----------------------------|------------------------------|------------------------------|
| Subject group type                              | Reporting group            | Reporting group             | Reporting group              | Reporting group              |
| Number of subjects analysed                     | 57                         | 53                          | 64                           | 58                           |
| Units: mg/dL                                    |                            |                             |                              |                              |
| least squares mean (confidence interval<br>90%) | -9.10 (-16.80<br>to -1.41) | -12.73 (-20.53<br>to -4.93) | -26.23 (-33.57<br>to -18.89) | -29.74 (-37.26<br>to -22.23) |

| <b>End point values</b>                         | PF-06882961<br>80mg BID      | PF-06882961<br>120mg BID     |  |  |
|---|------------------------------|------------------------------|--|--|
| Subject group type                              | Reporting group              | Reporting group              |  |  |
| Number of subjects analysed                     | 48                           | 42                           |  |  |
| Units: mg/dL                                    |                              |                              |  |  |
| least squares mean (confidence interval<br>90%) | -33.22 (-41.36<br>to -25.09) | -34.31 (-42.46<br>to -26.16) |  |  |

## Statistical analyses

| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
|---|--------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 110                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.5449                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -3.63                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -13.51                               |
| upper limit                             | 6.25                                 |

| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 121                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0031                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -17.12                              |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -26.62  |
| upper limit         | -7.63   |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 115                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0005                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -20.64                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -30.31                              |
| upper limit                             | -10.96                              |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 105                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -24.12                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -34.2                               |
| upper limit                             | -14.04                              |

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 120mg BID versus Placebo |
| Comparison groups                 | Placebo v PF-06882961 120mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 99                    |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | < 0.0001              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -25.21                |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -35.44                |
| upper limit                             | -14.97                |

## Secondary: Change From Baseline in Fasting Plasma Glucose at Week 12

|                        |   |
|------------------------|---|
| End point title        | Change From Baseline in Fasting Plasma Glucose at Week 12   |
| End point description: | The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |
| End point type         | Secondary   |
| End point timeframe:   | Baseline, Week 12   |

| End point values                             | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID   | PF-06882961<br>40mg BID   |
|--|-----------------------|--------------------------|---------------------------|---------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group           | Reporting group           |
| Number of subjects analysed                  | 55                    | 53                       | 63                        | 58                        |
| Units: mg/dL                                 |                       |                          |                           |                           |
| least squares mean (confidence interval 90%) | 1.21 (-7.93 to 10.35) | -6.49 (-15.70 to 2.73)   | -22.56 (-31.17 to -13.95) | -32.01 (-40.89 to -23.14) |

| End point values                             | PF-06882961<br>80mg BID   | PF-06882961<br>120mg BID  |  |  |
|--|---------------------------|---------------------------|--|--|
| Subject group type                           | Reporting group           | Reporting group           |  |  |
| Number of subjects analysed                  | 46                        | 37                        |  |  |
| Units: mg/dL                                 |                           |                           |  |  |
| least squares mean (confidence interval 90%) | -30.45 (-40.26 to -20.64) | -32.38 (-42.83 to -21.94) |  |  |

## Statistical analyses

|                            |                                      |
|----------------------------|--------------------------------------|
| Statistical analysis title | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups          | Placebo v PF-06882961 2.5mg BID      |



|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 108                   |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | = 0.294               |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -7.7                  |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -19.78                |
| upper limit                             | 4.38                  |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 118                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0008                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -23.77                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -35.37                              |
| upper limit                             | -12.17                              |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 113                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -33.23                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -45.05                              |
| upper limit                             | -21.4                               |

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 80mg BID versus Placebo |
|-----------------------------------|-------------------------------------|

|   |                                |
|---|--------------------------------|
| Comparison groups                       | Placebo v PF-06882961 80mg BID |
| Number of subjects included in analysis | 101                            |
| Analysis specification                  | Pre-specified                  |
| Analysis type                           | superiority                    |
| P-value                                 | < 0.0001                       |
| Method                                  | Mixed models analysis          |
| Parameter estimate                      | Difference in LS Mean          |
| Point estimate                          | -31.66                         |
| Confidence interval                     |                                |
| level                                   | 90 %                           |
| sides                                   | 2-sided                        |
| lower limit                             | -44.14                         |
| upper limit                             | -19.19                         |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 92                                   |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | < 0.0001                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -33.59                               |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -46.67                               |
| upper limit                             | -20.51                               |

## Secondary: Change From Baseline in Fasting Plasma Glucose at Week 16

|                        |   |
|------------------------|---|
| End point title        | Change From Baseline in Fasting Plasma Glucose at Week 16   |
| End point description: | The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |
| End point type         | Secondary   |
| End point timeframe:   |   |
| Baseline, Week 16      |   |

| <b>End point values</b>                      | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID   | PF-06882961<br>40mg BID   |
|--|-----------------------|--------------------------|---------------------------|---------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group           | Reporting group           |
| Number of subjects analysed                  | 52                    | 52                       | 61                        | 56                        |
| Units: mg/dL                                 |                       |                          |                           |                           |
| least squares mean (confidence interval 90%) | 1.31 (-7.58 to 10.20) | -12.81 (-21.71 to -3.91) | -24.53 (-32.88 to -16.18) | -30.47 (-39.06 to -21.87) |

| <b>End point values</b>                      | PF-06882961<br>80mg BID   | PF-06882961<br>120mg BID  |  |  |
|--|---------------------------|---------------------------|--|--|
| Subject group type                           | Reporting group           | Reporting group           |  |  |
| Number of subjects analysed                  | 45                        | 38                        |  |  |
| Units: mg/dL                                 |                           |                           |  |  |
| least squares mean (confidence interval 90%) | -25.71 (-35.15 to -16.26) | -31.93 (-41.73 to -22.13) |  |  |

## Statistical analyses

| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
|---|--------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 104                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.0464                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -14.12                               |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -25.77                               |
| upper limit                             | -2.47                                |

| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 113                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0002                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -25.84                              |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -37.05  |
| upper limit         | -14.62  |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 108                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -31.78                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -43.2                               |
| upper limit                             | -20.35                              |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 97                                  |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0002                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -27.02                              |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -39.03                              |
| upper limit                             | -15.01                              |

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 120mg BID versus Placebo |
| Comparison groups                 | Placebo v PF-06882961 120mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 90                    |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | < 0.0001              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -33.24                |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -45.63                |
| upper limit                             | -20.84                |

## Secondary: Change From Baseline in Body Weight at Week 2

|                        |   |
|------------------------|---|
| End point title        | Change From Baseline in Body Weight at Week 2   |
| End point description: | Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |
| End point type         | Secondary   |
| End point timeframe:   |   |
| Baseline, Week 2       |   |

| End point values                             | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 65                    | 64                       | 68                      | 68                      |
| Units: Kilogram                              |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.15 (-0.47 to 0.17) | -0.09 (-0.41 to 0.23)    | -0.12 (-0.44 to 0.19)   | -0.23 (-0.54 to 0.08)   |

| End point values                             | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 63                      | 69                       |  |  |
| Units: Kilogram                              |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -0.57 (-0.89 to -0.24)  | -0.54 (-0.85 to -0.24)   |  |  |

## Statistical analyses

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 129                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.8011                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | 0.06                                 |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.33                                |
| upper limit                             | 0.44                                 |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 133                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.9149                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | 0.02                                |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.35                               |
| upper limit                             | 0.4                                 |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 133                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.7216                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.08                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.46                               |
| upper limit                             | 0.3                                 |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 128                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0758                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.42                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.8                                |
| upper limit                             | -0.03                               |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 134                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.086                              |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.4                                 |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.77                                |
| upper limit                             | -0.02                                |

#### **Secondary: Change From Baseline in Body Weight at Week 4**

|   |   |
|---|---|
| End point title   | Change From Baseline in Body Weight at Week 4 |
| End point description:  |   |
| Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |   |
| End point type  | Secondary                                     |
| End point timeframe:  |   |
| Baseline, Week 4  |   |

| <b>End point values</b>                      | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 61                    | 58                       | 68                      | 63                      |
| Units: Kilogram                              |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.25 (-0.64 to 0.15) | -0.33 (-0.72 to 0.07)    | -0.08 (-0.46 to 0.30)   | -0.77 (-1.15 to -0.39)  |

| <b>End point values</b>                      | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 55                      | 61                       |  |  |
| Units: Kilogram                              |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -1.05 (-1.45 to -0.64)  | -1.33 (-1.71 to -0.95)   |  |  |

## Statistical analyses

| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
|---|--------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 119                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.7898                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.08                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.59                                |
| upper limit                             | 0.42                                 |

| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 129                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.5829                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | 0.16                                |



|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -0.33   |
| upper limit         | 0.66    |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 124                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0827                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.52                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.02                               |
| upper limit                             | -0.03                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 116                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0101                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.8                                |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.31                               |
| upper limit                             | -0.29                               |

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 120mg BID versus Placebo |
| Comparison groups                 | Placebo v PF-06882961 120mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 122                   |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | = 0.0004              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -1.09                 |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -1.59                 |
| upper limit                             | -0.59                 |

## Secondary: Change From Baseline in Body Weight at Week 6

|   |   |
|---|---|
| End point title   | Change From Baseline in Body Weight at Week 6 |
| End point description:  |   |
| Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |   |
| End point type  | Secondary                                     |
| End point timeframe:  |   |
| Baseline, Week 6  |   |

| End point values                             | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 60                    | 55                       | 66                      | 60                      |
| Units: Kilogram                              |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.09 (-0.57 to 0.40) | -0.19 (-0.68 to 0.31)    | -0.32 (-0.78 to 0.15)   | -0.83 (-1.31 to -0.36)  |

| End point values                             | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 51                      | 53                       |  |  |
| Units: Kilogram                              |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -1.69 (-2.20 to -1.19)  | -2.34 (-2.83 to -1.85)   |  |  |

## Statistical analyses

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 115                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.7985                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -0.1                                 |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.75                                |
| upper limit                             | 0.55                                 |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 126                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.5484                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.23                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.86                               |
| upper limit                             | 0.4                                 |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 120                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0541                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.75                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.38                               |
| upper limit                             | -0.11                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 111                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -1.6                                |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -2.26                               |
| upper limit                             | -0.95                               |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 113                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | < 0.0001                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -2.25                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -2.9                                 |
| upper limit                             | -1.6                                 |

### Secondary: Change From Baseline in Body Weight at Week 8

|   |   |
|---|---|
| End point title   | Change From Baseline in Body Weight at Week 8 |
| End point description:  |   |
| Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |   |
| End point type  | Secondary                                     |
| End point timeframe:  |   |
| Baseline, Week 8  |   |

| <b>End point values</b>                      | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 57                    | 54                       | 66                      | 58                      |
| Units: Kilogram                              |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.36 (-0.89 to 0.16) | -0.05 (-0.59 to 0.49)    | -0.27 (-0.78 to 0.23)   | -1.09 (-1.60 to -0.57)  |

| <b>End point values</b>                      | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 48                      | 42                       |  |  |
| Units: Kilogram                              |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -1.97 (-2.52 to -1.42)  | -3.31 (-3.85 to -2.77)   |  |  |

## Statistical analyses

| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
|---|--------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 111                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.4692                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | 0.31                                 |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.4                                 |
| upper limit                             | 1.03                                 |

| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 123                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.8274                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | 0.09                                |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -0.6    |
| upper limit         | 0.78    |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 115                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0887                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.72                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.42                               |
| upper limit                             | -0.02                               |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 105                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0003                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -1.61                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -2.33                               |
| upper limit                             | -0.88                               |

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 120mg BID versus Placebo |
| Comparison groups                 | Placebo v PF-06882961 120mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 99                    |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | < 0.0001              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -2.95                 |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -3.67                 |
| upper limit                             | -2.22                 |

## Secondary: Change From Baseline in Body Weight at Week 12

|                        |   |
|------------------------|---|
| End point title        | Change From Baseline in Body Weight at Week 12  |
| End point description: | Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |
| End point type         | Secondary   |
| End point timeframe:   |   |
| Baseline, Week 12      |   |

| End point values                             | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 55                    | 53                       | 63                      | 58                      |
| Units: Kilogram                              |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.24 (-0.85 to 0.38) | -0.09 (-0.72 to 0.53)    | -0.00 (-0.59 to 0.58)   | -1.05 (-1.65 to -0.44)  |

| End point values                             | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 46                      | 38                       |  |  |
| Units: Kilogram                              |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -2.52 (-3.17 to -1.87)  | -3.81 (-4.46 to -3.16)   |  |  |

## Statistical analyses

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 108                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.7758                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | 0.15                                 |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.7                                 |
| upper limit                             | 0.99                                 |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 118                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.6367                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | 0.23                                |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -0.58                               |
| upper limit                             | 1.05                                |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 113                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.1082                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.81                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.63                               |
| upper limit                             | 0.02                                |



|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 101                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.0001                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -2.28                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -3.14                               |
| upper limit                             | -1.42                               |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 120mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 120mg BID      |
| Number of subjects included in analysis | 93                                   |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | < 0.0001                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | -3.57                                |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -4.44                                |
| upper limit                             | -2.7                                 |

## Secondary: Change From Baseline in Body Weight at Week 16

|   |  |
|---|--|
| End point title   | Change From Baseline in Body Weight at Week 16 |
| End point description:  |  |
| Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment. |  |
| End point type  | Secondary                                      |
| End point timeframe:  |  |
| Baseline, Week 16   |  |

| <b>End point values</b>                      | Placebo               | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------------|--------------------------|-------------------------|-------------------------|
| Subject group type                           | Reporting group       | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                  | 52                    | 53                       | 62                      | 57                      |
| Units: Kilogram                              |                       |                          |                         |                         |
| least squares mean (confidence interval 90%) | -0.43 (-1.12 to 0.25) | 0.02 (-0.68 to 0.72)     | -0.06 (-0.71 to 0.60)   | -1.16 (-1.84 to -0.49)  |

| <b>End point values</b>                      | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                           | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                  | 46                      | 38                       |  |  |
| Units: Kilogram                              |                         |                          |  |  |
| least squares mean (confidence interval 90%) | -2.48 (-3.20 to -1.75)  | -4.60 (-5.34 to -3.86)   |  |  |

### Statistical analyses

| <b>Statistical analysis title</b>       | PF-06882961 2.5mg BID versus Placebo |
|---|--------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 2.5mg BID      |
| Number of subjects included in analysis | 105                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.4325                             |
| Method                                  | Mixed models analysis                |
| Parameter estimate                      | Difference in LS Mean                |
| Point estimate                          | 0.45                                 |
| Confidence interval                     |                                      |
| level                                   | 90 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | -0.5                                 |
| upper limit                             | 1.41                                 |

| <b>Statistical analysis title</b>       | PF-06882961 10mg BID versus Placebo |
|---|-------------------------------------|
| Comparison groups                       | Placebo v PF-06882961 10mg BID      |
| Number of subjects included in analysis | 114                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.4978                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | 0.38                                |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | -0.54   |
| upper limit         | 1.3     |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 40mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 40mg BID      |
| Number of subjects included in analysis | 109                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.197                             |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -0.73                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -1.66                               |
| upper limit                             | 0.2                                 |

|   |                                     |
|---|-------------------------------------|
| <b>Statistical analysis title</b>       | PF-06882961 80mg BID versus Placebo |
| Comparison groups                       | Placebo v PF-06882961 80mg BID      |
| Number of subjects included in analysis | 98                                  |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | = 0.0006                            |
| Method                                  | Mixed models analysis               |
| Parameter estimate                      | Difference in LS Mean               |
| Point estimate                          | -2.04                               |
| Confidence interval                     |                                     |
| level                                   | 90 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -3.01                               |
| upper limit                             | -1.07                               |

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| <b>Statistical analysis title</b> | PF-06882961 120mg BID versus Placebo |
| Comparison groups                 | Placebo v PF-06882961 120mg BID      |

|   |                       |
|---|-----------------------|
| Number of subjects included in analysis | 90                    |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | superiority           |
| P-value                                 | < 0.0001              |
| Method                                  | Mixed models analysis |
| Parameter estimate                      | Difference in LS Mean |
| Point estimate                          | -4.17                 |
| Confidence interval                     |                       |
| level                                   | 90 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -5.15                 |
| upper limit                             | -3.18                 |

### Secondary: Number of Subjects With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])

|                 |  |
|-----------------|--|
| End point title | Number of Subjects With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs]) |
|-----------------|--|

End point description:

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent. Safety analysis set included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 21

| End point values                                | Placebo         | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|---|-----------------|--------------------------|-------------------------|-------------------------|
| Subject group type                              | Reporting group | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                     | 66              | 68                       | 68                      | 71                      |
| Units: Subjects                                 |                 |                          |                         |                         |
| Number of Subjects With Treatment Emergent AEs  | 32              | 32                       | 31                      | 42                      |
| Number of Subjects With Treatment Emergent SAEs | 1               | 1                        | 2                       | 6                       |

| End point values                               | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                             | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                    | 67                      | 71                       |  |  |
| Units: Subjects                                |                         |                          |  |  |
| Number of Subjects With Treatment Emergent AEs | 43                      | 44                       |  |  |

|   |   |   |  |  |
|---|---|---|--|--|
| Number of Subjects With Treatment Emergent SAEs | 2 | 1 |  |  |
|---|---|---|--|--|

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality

|                 |   |
|-----------------|---|
| End point title | Number of Subjects With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality |
|-----------------|---|

End point description:

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, PT/INR, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin); lipid panel (low density lipoprotein cholesterol, high density lipoprotein cholesterol). Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment and had at least 1 measurement available.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline Through Week 21

| End point values                                 | Placebo         | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|--|-----------------|--------------------------|-------------------------|-------------------------|
| Subject group type                               | Reporting group | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                      | 65              | 68                       | 68                      | 71                      |
| Units: Subjects                                  |                 |                          |                         |                         |
| Number of Subjects With Laboratory Abnormalities | 60              | 57                       | 57                      | 57                      |

| End point values                                 | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|--|-------------------------|--------------------------|--|--|
| Subject group type                               | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                      | 67                      | 71                       |  |  |
| Units: Subjects                                  |                         |                          |  |  |
| Number of Subjects With Laboratory Abnormalities | 60                      | 64                       |  |  |

## Statistical analyses

**Secondary: Number of Subjects With Treatment Emergent Vital Signs Abnormalities**

|   |  |
|---|--|
| End point title   | Number of Subjects With Treatment Emergent Vital Signs Abnormalities |
| End point description:  |  |
| Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) <50 mmHg; 3) supine pulse rate <40 or >120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to ( $\geq$ ) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP $\geq$ 20 mmHg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment, took at least 1 dose of study treatment and had at least 1 measurement available. |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Baseline through Week 21  |  |

| End point values                   | Placebo         | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|------------------------------------|-----------------|--------------------------|-------------------------|-------------------------|
| Subject group type                 | Reporting group | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed        | 65              | 68                       | 68                      | 71                      |
| Units: Subjects                    |                 |                          |                         |                         |
| Supine SBP <90 mmHg                | 0               | 0                        | 0                       | 0                       |
| Supine SBP increase $\geq$ 30 mmHg | 3               | 4                        | 3                       | 3                       |
| Supine SBP decrease $\geq$ 30 mmHg | 4               | 4                        | 3                       | 5                       |
| Supine DBP <50 mmHg                | 1               | 0                        | 0                       | 1                       |
| Supine DBP increase $\geq$ 20 mmHg | 1               | 1                        | 2                       | 3                       |
| Supine DBP decrease $\geq$ 20 mmHg | 3               | 4                        | 1                       | 3                       |
| Supine pulse rate <40 bpm          | 0               | 0                        | 0                       | 0                       |
| Supine pulse rate >120 bpm         | 0               | 0                        | 0                       | 0                       |

| End point values                   | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|------------------------------------|-------------------------|--------------------------|--|--|
| Subject group type                 | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed        | 67                      | 71                       |  |  |
| Units: Subjects                    |                         |                          |  |  |
| Supine SBP <90 mmHg                | 0                       | 0                        |  |  |
| Supine SBP increase $\geq$ 30 mmHg | 0                       | 5                        |  |  |
| Supine SBP decrease $\geq$ 30 mmHg | 5                       | 0                        |  |  |
| Supine DBP <50 mmHg                | 0                       | 1                        |  |  |
| Supine DBP increase $\geq$ 20 mmHg | 3                       | 3                        |  |  |
| Supine DBP decrease $\geq$ 20 mmHg | 2                       | 1                        |  |  |
| Supine pulse rate <40 bpm          | 0                       | 0                        |  |  |
| Supine pulse rate >120 bpm         | 0                       | 0                        |  |  |

**Statistical analyses**

**Secondary: Number of Subjects With Treatment Emergent ECG Abnormalities**

|  |  |
|--|--|
| End point title  | Number of Subjects With Treatment Emergent ECG Abnormalities |
| End point description:   |  |
| ECG categorical abnormality criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to ( $\geq$ ) 300 millisecond (msec), b) $\geq 25\%$ increase when baseline is $> 200$ msec or $\geq 50\%$ increase when baseline is less than or equal to ( $\leq$ ) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) $\geq 140$ msec, b) $\geq 50\%$ increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) $> 450$ msec and $\leq 480$ msec, b) $> 480$ msec and $\leq 500$ msec, c) $> 500$ msec, d) $> 30$ msec and $\leq 60$ msec increase from baseline, e) $> 60$ msec increase from baseline. Overall number of subjects analyzed included all subjects randomly assigned to study treatment, took at least 1 dose of study treatment and had at least 1 measurement available. |  |
| End point type   | Secondary  |
| End point timeframe:   |  |
| Baseline Through Week 21   |  |

| End point values                                  | Placebo         | PF-06882961<br>2.5mg BID | PF-06882961<br>10mg BID | PF-06882961<br>40mg BID |
|---|-----------------|--------------------------|-------------------------|-------------------------|
| Subject group type                                | Reporting group | Reporting group          | Reporting group         | Reporting group         |
| Number of subjects analysed                       | 65              | 68                       | 68                      | 71                      |
| Units: Subjects                                   |                 |                          |                         |                         |
| PR interval $\geq 300$ msec                       | 0               | 0                        | 0                       | 0                       |
| %Change in PR interval $\geq 25/50\%$             | 3               | 0                        | 0                       | 0                       |
| QRS interval $\geq 140$ msec                      | 1               | 1                        | 0                       | 0                       |
| %Change in QRS interval $\geq 50\%$               | 1               | 1                        | 0                       | 0                       |
| QTcF interval $> 450$ and $\leq 480$ msec         | 2               | 3                        | 2                       | 1                       |
| QTcF interval $> 480$ and $\leq 500$ msec         | 0               | 0                        | 0                       | 0                       |
| QTcF interval $> 500$ msec                        | 0               | 0                        | 0                       | 0                       |
| Change in QTcF interval $> 30$ and $\leq 60$ msec | 2               | 3                        | 2                       | 6                       |
| Change in QTcF interval $> 60$ msec               | 0               | 0                        | 1                       | 1                       |

| End point values                                  | PF-06882961<br>80mg BID | PF-06882961<br>120mg BID |  |  |
|---|-------------------------|--------------------------|--|--|
| Subject group type                                | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed                       | 67                      | 71                       |  |  |
| Units: Subjects                                   |                         |                          |  |  |
| PR interval $\geq 300$ msec                       | 0                       | 1                        |  |  |
| %Change in PR interval $\geq 25/50\%$             | 1                       | 0                        |  |  |
| QRS interval $\geq 140$ msec                      | 0                       | 0                        |  |  |
| %Change in QRS interval $\geq 50\%$               | 0                       | 0                        |  |  |
| QTcF interval $> 450$ and $\leq 480$ msec         | 3                       | 4                        |  |  |
| QTcF interval $> 480$ and $\leq 500$ msec         | 0                       | 1                        |  |  |
| QTcF interval $> 500$ msec                        | 0                       | 0                        |  |  |
| Change in QTcF interval $> 30$ and $\leq 60$ msec | 3                       | 6                        |  |  |

|                                  |   |   |  |  |
|----------------------------------|---|---|--|--|
| Change in QTcF interval >60 msec | 0 | 3 |  |  |
|----------------------------------|---|---|--|--|

### Statistical analyses

---

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 21

Adverse event reporting additional description:

For the number of adverse events, if the same subject in a given treatment had more than 1 occurrence in the same preferred term event category, the preferred term event for the subject was counted once, and only the most severe occurrence was counted.

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 24.0 |
|--------------------|------|

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.

|                       |                       |
|-----------------------|-----------------------|
| Reporting group title | PF-06882961 2.5mg BID |
|-----------------------|-----------------------|

Reporting group description:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

|                       |                      |
|-----------------------|----------------------|
| Reporting group title | PF-06882961 10mg BID |
|-----------------------|----------------------|

Reporting group description:

PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

|                       |                      |
|-----------------------|----------------------|
| Reporting group title | PF-06882961 40mg BID |
|-----------------------|----------------------|

Reporting group description:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

|                       |                      |
|-----------------------|----------------------|
| Reporting group title | PF-06882961 80mg BID |
|-----------------------|----------------------|

Reporting group description:

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

|                       |                       |
|-----------------------|-----------------------|
| Reporting group title | PF-06882961 120mg BID |
|-----------------------|-----------------------|

Reporting group description:

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

| Serious adverse events                            | Placebo        | PF-06882961 2.5mg BID | PF-06882961 10mg BID |
|---|----------------|-----------------------|----------------------|
| Total subjects affected by serious adverse events |                |                       |                      |
| subjects affected / exposed                       | 1 / 66 (1.52%) | 1 / 68 (1.47%)        | 2 / 68 (2.94%)       |
| number of deaths (all causes)                     | 0              | 1                     | 0                    |
| number of deaths resulting from adverse events    | 0              | 1                     | 0                    |
| Investigations                                    |                |                       |                      |
| Gamma-glutamyltransferase increased               |                |                       |                      |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed   | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| SARS-CoV-2 test positive  |                |                |                |
| subjects affected / exposed   | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |                |                |
| Squamous cell carcinoma   |                |                |                |
| subjects affected / exposed   | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications                      |                |                |                |
| Ankle fracture  |                |                |                |
| subjects affected / exposed   | 1 / 66 (1.52%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Seroma  |                |                |                |
| subjects affected / exposed   | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Vascular disorders  |                |                |                |
| Hypertension  |                |                |                |
| subjects affected / exposed   | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders   |                |                |                |
| Acute myocardial infarction   |                |                |                |
| subjects affected / exposed   | 0 / 66 (0.00%) | 1 / 68 (1.47%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Palpitations  |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Multiple sclerosis                              |                |                |                |
| subjects affected / exposed                     | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 1 / 68 (1.47%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Paraesthesia                                    |                |                |                |
| subjects affected / exposed                     | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Blood and lymphatic system disorders            |                |                |                |
| Anaemia   |                |                |                |
| subjects affected / exposed                     | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 1 / 68 (1.47%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                |                |                |
| Cholecystitis acute                             |                |                |                |
| subjects affected / exposed                     | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Drug-induced liver injury                       |                |                |                |
| subjects affected / exposed                     | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| COVID-19 pneumonia                              |                |                |                |
| subjects affected / exposed                     | 0 / 66 (0.00%) | 1 / 68 (1.47%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1          | 0 / 0          |
| Pneumonia                                       |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 66 (0.00%) | 0 / 68 (0.00%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| <b>Serious adverse events</b>                                       | PF-06882961 40mg<br>BID | PF-06882961 80mg<br>BID | PF-06882961<br>120mg BID |
|---|-------------------------|-------------------------|--------------------------|
| Total subjects affected by serious adverse events                   |                         |                         |                          |
| subjects affected / exposed   | 6 / 71 (8.45%)          | 2 / 67 (2.99%)          | 1 / 71 (1.41%)           |
| number of deaths (all causes)                                       | 2                       | 0                       | 0                        |
| number of deaths resulting from adverse events                      | 2                       | 0                       | 0                        |
| Investigations  |                         |                         |                          |
| Gamma-glutamyltransferase increased                                 |                         |                         |                          |
| subjects affected / exposed   | 1 / 71 (1.41%)          | 0 / 67 (0.00%)          | 0 / 71 (0.00%)           |
| occurrences causally related to treatment / all                     | 0 / 1                   | 0 / 0                   | 0 / 0                    |
| deaths causally related to treatment / all                          | 0 / 0                   | 0 / 0                   | 0 / 0                    |
| SARS-CoV-2 test positive  |                         |                         |                          |
| subjects affected / exposed   | 1 / 71 (1.41%)          | 0 / 67 (0.00%)          | 0 / 71 (0.00%)           |
| occurrences causally related to treatment / all                     | 0 / 1                   | 0 / 0                   | 0 / 0                    |
| deaths causally related to treatment / all                          | 0 / 1                   | 0 / 0                   | 0 / 0                    |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                         |                         |                          |
| Squamous cell carcinoma   |                         |                         |                          |
| subjects affected / exposed   | 0 / 71 (0.00%)          | 0 / 67 (0.00%)          | 1 / 71 (1.41%)           |
| occurrences causally related to treatment / all                     | 0 / 0                   | 0 / 0                   | 0 / 1                    |
| deaths causally related to treatment / all                          | 0 / 0                   | 0 / 0                   | 0 / 0                    |
| Injury, poisoning and procedural complications                      |                         |                         |                          |
| Ankle fracture  |                         |                         |                          |
| subjects affected / exposed   | 0 / 71 (0.00%)          | 0 / 67 (0.00%)          | 0 / 71 (0.00%)           |
| occurrences causally related to treatment / all                     | 0 / 0                   | 0 / 0                   | 0 / 0                    |
| deaths causally related to treatment / all                          | 0 / 0                   | 0 / 0                   | 0 / 0                    |
| Seroma  |                         |                         |                          |
| subjects affected / exposed   | 1 / 71 (1.41%)          | 0 / 67 (0.00%)          | 0 / 71 (0.00%)           |
| occurrences causally related to treatment / all                     | 0 / 1                   | 0 / 0                   | 0 / 0                    |
| deaths causally related to treatment / all                          | 0 / 0                   | 0 / 0                   | 0 / 0                    |
| Vascular disorders  |                         |                         |                          |
| Hypertension  |                         |                         |                          |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 71 (0.00%) | 1 / 67 (1.49%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Cardiac disorders</b>                        |                |                |                |
| Acute myocardial infarction                     |                |                |                |
| subjects affected / exposed                     | 0 / 71 (0.00%) | 0 / 67 (0.00%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Palpitations                                    |                |                |                |
| subjects affected / exposed                     | 1 / 71 (1.41%) | 0 / 67 (0.00%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Nervous system disorders</b>                 |                |                |                |
| Multiple sclerosis                              |                |                |                |
| subjects affected / exposed                     | 0 / 71 (0.00%) | 0 / 67 (0.00%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Paraesthesia                                    |                |                |                |
| subjects affected / exposed                     | 1 / 71 (1.41%) | 0 / 67 (0.00%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Blood and lymphatic system disorders</b>     |                |                |                |
| Anaemia   |                |                |                |
| subjects affected / exposed                     | 0 / 71 (0.00%) | 0 / 67 (0.00%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Hepatobiliary disorders</b>                  |                |                |                |
| Cholecystitis acute                             |                |                |                |
| subjects affected / exposed                     | 0 / 71 (0.00%) | 1 / 67 (1.49%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Drug-induced liver injury                       |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 71 (1.41%) | 0 / 67 (0.00%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Infections and infestations</b>              |                |                |                |
| COVID-19 pneumonia                              |                |                |                |
| subjects affected / exposed                     | 1 / 71 (1.41%) | 0 / 67 (0.00%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 0          |
| <b>Pneumonia</b>                                |                |                |                |
| subjects affected / exposed                     | 1 / 71 (1.41%) | 0 / 67 (0.00%) | 0 / 71 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                            | Placebo          | PF-06882961 2.5mg<br>BID | PF-06882961 10mg<br>BID |
|--|------------------|--------------------------|-------------------------|
| <b>Total subjects affected by non-serious adverse events</b> |                  |                          |                         |
| subjects affected / exposed                                  | 15 / 66 (22.73%) | 21 / 68 (30.88%)         | 17 / 68 (25.00%)        |
| <b>Investigations</b>  |                  |                          |                         |
| SARS-CoV-2 test positive                                     |                  |                          |                         |
| subjects affected / exposed                                  | 2 / 66 (3.03%)   | 4 / 68 (5.88%)           | 3 / 68 (4.41%)          |
| occurrences (all)  | 2                | 4                        | 3                       |
| <b>Vascular disorders</b>                                    |                  |                          |                         |
| Hypertension   |                  |                          |                         |
| subjects affected / exposed                                  | 0 / 66 (0.00%)   | 1 / 68 (1.47%)           | 3 / 68 (4.41%)          |
| occurrences (all)  | 0                | 1                        | 3                       |
| <b>Nervous system disorders</b>                              |                  |                          |                         |
| Dizziness  |                  |                          |                         |
| subjects affected / exposed                                  | 1 / 66 (1.52%)   | 1 / 68 (1.47%)           | 4 / 68 (5.88%)          |
| occurrences (all)  | 1                | 2                        | 4                       |
| Headache   |                  |                          |                         |
| subjects affected / exposed                                  | 4 / 66 (6.06%)   | 4 / 68 (5.88%)           | 1 / 68 (1.47%)          |
| occurrences (all)  | 4                | 4                        | 1                       |
| <b>Gastrointestinal disorders</b>                            |                  |                          |                         |
| Abdominal distension   |                  |                          |                         |

|  |                         |                         |                          |
|--|-------------------------|-------------------------|--------------------------|
| subjects affected / exposed                              | 1 / 66 (1.52%)          | 0 / 68 (0.00%)          | 1 / 68 (1.47%)           |
| occurrences (all)  | 1                       | 0                       | 1                        |
| Diarrhoea  |                         |                         |                          |
| subjects affected / exposed                              | 2 / 66 (3.03%)          | 3 / 68 (4.41%)          | 4 / 68 (5.88%)           |
| occurrences (all)  | 2                       | 3                       | 6                        |
| Dyspepsia  |                         |                         |                          |
| subjects affected / exposed                              | 0 / 66 (0.00%)          | 4 / 68 (5.88%)          | 3 / 68 (4.41%)           |
| occurrences (all)  | 0                       | 4                       | 3                        |
| Gastrooesophageal reflux disease                         |                         |                         |                          |
| subjects affected / exposed                              | 0 / 66 (0.00%)          | 1 / 68 (1.47%)          | 2 / 68 (2.94%)           |
| occurrences (all)  | 0                       | 1                       | 2                        |
| Nausea   |                         |                         |                          |
| subjects affected / exposed                              | 2 / 66 (3.03%)          | 5 / 68 (7.35%)          | 5 / 68 (7.35%)           |
| occurrences (all)  | 2                       | 5                       | 7                        |
| Vomiting   |                         |                         |                          |
| subjects affected / exposed                              | 0 / 66 (0.00%)          | 0 / 68 (0.00%)          | 1 / 68 (1.47%)           |
| occurrences (all)  | 0                       | 0                       | 1                        |
| Infections and infestations                              |                         |                         |                          |
| Urinary tract infection                                  |                         |                         |                          |
| subjects affected / exposed                              | 0 / 66 (0.00%)          | 1 / 68 (1.47%)          | 0 / 68 (0.00%)           |
| occurrences (all)  | 0                       | 1                       | 0                        |
| Metabolism and nutrition disorders                       |                         |                         |                          |
| Decreased appetite                                       |                         |                         |                          |
| subjects affected / exposed                              | 0 / 66 (0.00%)          | 2 / 68 (2.94%)          | 0 / 68 (0.00%)           |
| occurrences (all)  | 0                       | 3                       | 0                        |
| Hyperglycaemia   |                         |                         |                          |
| subjects affected / exposed                              | 6 / 66 (9.09%)          | 2 / 68 (2.94%)          | 1 / 68 (1.47%)           |
| occurrences (all)  | 6                       | 4                       | 1                        |
| Hypoglycaemia  |                         |                         |                          |
| subjects affected / exposed                              | 0 / 66 (0.00%)          | 1 / 68 (1.47%)          | 1 / 68 (1.47%)           |
| occurrences (all)  | 0                       | 1                       | 1                        |
| <b>Non-serious adverse events</b>                        | PF-06882961 40mg<br>BID | PF-06882961 80mg<br>BID | PF-06882961<br>120mg BID |
| Total subjects affected by non-serious<br>adverse events |                         |                         |                          |
| subjects affected / exposed                              | 33 / 71 (46.48%)        | 40 / 67 (59.70%)        | 35 / 71 (49.30%)         |
| Investigations   |                         |                         |                          |

|  |   |   |  |
|--|---|---|--|
| SARS-CoV-2 test positive<br>subjects affected / exposed<br>occurrences (all)   | 2 / 71 (2.82%)<br>2   | 1 / 67 (1.49%)<br>1   | 1 / 71 (1.41%)<br>1  |
| Vascular disorders<br>Hypertension<br>subjects affected / exposed<br>occurrences (all)   | 1 / 71 (1.41%)<br>1   | 4 / 67 (5.97%)<br>4   | 1 / 71 (1.41%)<br>1  |
| Nervous system disorders<br>Dizziness<br>subjects affected / exposed<br>occurrences (all)<br><br>Headache<br>subjects affected / exposed<br>occurrences (all)  | 3 / 71 (4.23%)<br>3<br><br>5 / 71 (7.04%)<br>5  | 1 / 67 (1.49%)<br>3<br><br>2 / 67 (2.99%)<br>3  | 5 / 71 (7.04%)<br>7<br><br>7 / 71 (9.86%)<br>9   |
| Gastrointestinal disorders<br>Abdominal distension<br>subjects affected / exposed<br>occurrences (all)<br><br>Diarrhoea<br>subjects affected / exposed<br>occurrences (all)<br><br>Dyspepsia<br>subjects affected / exposed<br>occurrences (all)<br><br>Gastrooesophageal reflux disease<br>subjects affected / exposed<br>occurrences (all)<br><br>Nausea<br>subjects affected / exposed<br>occurrences (all)<br><br>Vomiting<br>subjects affected / exposed<br>occurrences (all) | 4 / 71 (5.63%)<br>5<br><br>8 / 71 (11.27%)<br>10<br><br>2 / 71 (2.82%)<br>2<br><br>2 / 71 (2.82%)<br>2<br><br>11 / 71 (15.49%)<br>13<br><br>5 / 71 (7.04%)<br>6 | 3 / 67 (4.48%)<br>3<br><br>12 / 67 (17.91%)<br>14<br><br>9 / 67 (13.43%)<br>10<br><br>4 / 67 (5.97%)<br>4<br><br>22 / 67 (32.84%)<br>27<br><br>11 / 67 (16.42%)<br>17 | 2 / 71 (2.82%)<br>3<br><br>7 / 71 (9.86%)<br>7<br><br>2 / 71 (2.82%)<br>2<br><br>5 / 71 (7.04%)<br>5<br><br>23 / 71 (32.39%)<br>32<br><br>18 / 71 (25.35%)<br>37 |
| Infections and infestations<br>Urinary tract infection<br>subjects affected / exposed<br>occurrences (all)   | 5 / 71 (7.04%)<br>5   | 3 / 67 (4.48%)<br>4   | 1 / 71 (1.41%)<br>1  |



|                                    |                |                |                |
|------------------------------------|----------------|----------------|----------------|
| Metabolism and nutrition disorders |                |                |                |
| Decreased appetite                 |                |                |                |
| subjects affected / exposed        | 2 / 71 (2.82%) | 1 / 67 (1.49%) | 5 / 71 (7.04%) |
| occurrences (all)                  | 2              | 1              | 5              |
| Hyperglycaemia                     |                |                |                |
| subjects affected / exposed        | 0 / 71 (0.00%) | 4 / 67 (5.97%) | 0 / 71 (0.00%) |
| occurrences (all)                  | 0              | 4              | 0              |
| Hypoglycaemia                      |                |                |                |
| subjects affected / exposed        | 4 / 71 (5.63%) | 6 / 67 (8.96%) | 3 / 71 (4.23%) |
| occurrences (all)                  | 6              | 8              | 3              |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date        | Amendment   |
|-------------|---|
| 19 May 2020 | <ul style="list-style-type: none"><li>• Added exclusion of sulfasalazine (a breast cancer resistance protein [BCRP] substrate) from study as PF-06882961 has the potential to inhibit intestinal BCRP. Updated the nonclinical safety data to align with the available toxicology information (6 month toxicology study in cynomolgus monkeys).</li><li>• Added the minimum time frame of monthly between safety reviews to ensure that there was ample time to prepare all data reports and ensure a timely review of safety data. The interim analysis of unblinded safety data permitted possible updates to study conduct if needed.</li><li>• Lowered the cut off for blood pressure to a more conservative level to optimize blood pressure control prior to study entry.</li></ul> |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported